Entrada Therapeutics Q3 EPS $(0.94) Beats $(1.01) Estimate, Sales $905.000K Miss $5.871M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings BeatsEarnings Misses
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.01) by 6.93 percent. This is a 11.32 percent increase over losses of $(1.06) per share
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.01) by 6.93 percent. This is a 11.32 percent increase over losses of $(1.06) per share from the same period last year. The company reported quarterly sales of $905.000 thousand which missed the analyst consensus estimate of $5.871 million by 84.59 percent. This is a 43.93 percent decrease over sales of $1.614 million the same period last year.